Business Segment Information (Tables)

6 Months Ended

Mar. 31, 2020

The following illustrates reportable and operating segment disaggregated revenue as required by Accounting Standards Codification 606 for the periods indicated:



	Three months ended March 31,						Six months ended March 31,
(in thousands)	2020			2019			2020			2019
Pharmaceutical Distribution Services	$	45,562,670		$	41,676,164		$	91,599,498		$	85,420,545
Other:
MWI Animal Health	1,043,016			947,293			2,071,334			1,901,877
Global Commercialization Services	833,577			718,136			1,652,243			1,434,490
Total Other	1,876,593			1,665,429			3,723,577			3,336,367
Intersegment eliminations	(21,624		)	(21,991		)	(40,694		)	(44,858		)
Revenue	$	47,417,639		$	43,319,602		$	95,282,381		$	88,712,054

Segment operating income

The following illustrates reportable segment operating income for the periods indicated:



	Three months ended March 31,					Six months ended March 31,
(in thousands)	2020		2019			2020			2019
Pharmaceutical Distribution Services	$	563,097	$	517,034		$	954,791		$	890,241
Other	108,260		99,879			212,739			198,813
Intersegment eliminations	328		(249		)	(579		)	(556		)
Total segment operating income	$	671,685	$	616,664		$	1,166,951		$	1,088,498

Reconciliation of total segment operating income to income (loss) from operations before income taxes

The following reconciles total segment operating income to income before income taxes for the periods indicated:



	Three months ended March 31,						Six months ended March 31,
(in thousands)	2020			2019			2020			2019
Total segment operating income	$	671,685		$	616,664		$	1,166,951		$	1,088,498
Gain from antitrust litigation settlements	54			51,976			8,546			139,255
LIFO (expense) credit	(23,853		)	66,805			(37,134		)	69,834
PharMEDium remediation costs	—			(15,897		)	(16,165		)	(36,392		)
PharMEDium shutdown costs	(32,470		)	—			(32,470		)	—
New York State Opioid Stewardship Act	—			—			—			22,000
Contingent consideration adjustment	12,153			—			12,153			—
Acquisition-related intangibles amortization	(26,670		)	(46,594		)	(60,236		)	(91,746		)
Employee severance, litigation, and other	(67,732		)	(55,389		)	(107,041		)	(96,061		)
Impairment of PharMEDium assets	(223,652		)	(570,000		)	(361,652		)	(570,000		)
Operating income	309,515			47,565			572,952			525,388
Other (income) loss	(1,109		)	(14,494		)	1,733			(11,397		)
Interest expense, net	34,421			43,275			65,428			85,445
Income before income taxes	$	276,203		$	18,784		$	505,791		$	451,340